| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | SARS; SERS; SERRS; NEDMAS |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SARS1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于SARS1抗体的代表性文献(信息基于公开研究总结，具体引用需查证原文)：
1. **《Antibody response and correlates of infection in household contacts of patients with severe acute respiratory syndrome》**
- **作者**：Subbarao, K. 等(2004)
- **摘要**：研究SARS患者家庭接触者的抗体反应，发现康复者血清中的中和抗体(IgG)在感染后数月内持续存在，且与病毒清除和免疫保护相关。
2. **《Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies》**
- **作者**：Sui, J. 等(2004)
- **摘要**：报道从康复患者中分离出单克隆抗体(如80R)，可特异性结合SARS1刺突蛋白(S蛋白)，并展示跨毒株的中和能力，为抗体治疗提供依据。
3. **《Long-term persistence of IgG antibodies in SARS-CoV infection》**
- **作者**：Cao, W. C. 等(2006)
- **摘要**：追踪SARS康复患者发现，IgG抗体在感染后至少3年内持续存在，但中和活性随时间逐渐下降，提示免疫记忆的长期性。
4. **《Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection》**
- **作者**：Tang, F. 等(2011)
- **摘要**：研究SARS康复者长期免疫反应，发现尽管抗体水平降低，但T细胞免疫与部分残留抗体共同作用可能提供持续保护。
(注：以上为简化概括，实际文献需通过PubMed或学术数据库查询原文确认细节。)
SARS-CoV-1 antibodies emerged following the 2002-2003 outbreak of severe acute respiratory syndrome (SARS) caused by the SARS-CoV-1 coronavirus. These antibodies are immune proteins produced by B cells, primarily targeting the viral spike (S) glycoprotein, which mediates host cell entry by binding to angiotensin-converting enzyme 2 (ACE2) receptors. Neutralizing antibodies block this interaction, preventing viral infection. Studies identified both IgM (early response) and IgG (long-term immunity) antibodies, with IgG persisting for years in recovered patients, though titers gradually decline.
Research revealed that SARS-CoV-1 antibodies exhibit cross-reactivity with other coronaviruses, including SARS-CoV-2. due to conserved regions in the S protein. However, antibody-dependent enhancement (ADE) of infection was a concern, as some subneutralizing antibodies were shown to facilitate viral entry into immune cells in vitro, though clinical relevance remains unclear. Monoclonal antibodies (mAbs) like CR3022. isolated from convalescent patients, demonstrated potent neutralization and informed therapeutic development. Structural studies mapped epitopes to the receptor-binding domain (RBD) and other S protein regions, guiding vaccine design.
SARS-CoV-1 antibody research laid groundwork for COVID-19 responses, highlighting the importance of neutralizing epitopes, immune memory, and potential risks like ADE. These insights remain critical for pandemic preparedness against novel coronaviruses.
×
